Tianjin Medical University Second Hospital

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

7 drugs in development

Phase 26

Preclinical1

By Therapeutic Area

top 1

Oncology

444%

R&D Momentum

64/100

Pipeline Velocity

34/100

Trial Completion Rate

100/100

Pipeline Concentration

51/100

Pipeline Freshness

68/100

Strategic Signals

↗Early-stage heavy pipeline may seek late-stage partners

Activity

Recent Activity

Last 14 days

Nov 5, 2026

Recruiting

AI Agent-Enabled Whole-Course Management to Improve Anticancer Medication Safety and Reduce Healthcare Burden in Advanced Solid Tumors: A Prospective, Single-Center, Non-Randomized, Parallel-Group Real-World Controlled Study

Nov 4, 2026

Recruiting

The Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer: An Open-Label, Randomized Controlled, Multi-Center Clinical Study (Truce-LB01)

Oct 31, 2026

Recruiting

A Multicenter, Multi-Arm, Exploratory Platform Clinical Study on the Therapeutic Efficacy of Organoid Drug Sensitivity-Guided Treatment in Patients With Refractory Tumors

Earlier

Oct 16, 2026TrialRandomized Trial of Active Surveillance Versus Continued Systemic Immunotherapy After Achieving Tumor-Free Status in Extensive Transurethrally Unresectable Very-High-Risk NMIBC

Oct 10, 2026TrialA Prospective, Multicenter, Randomized, Open-Label, Non-Inferiority Trial of Active Surveillance Versus Adjuvant Intravesical Chemotherapy After Complete Transurethral Resection in Patients With Preoperative Liquid Biopsy-Negative, Intermediate-Risk Non-Muscle-Invasive Bladder Cancer

Sep 29, 2026TrialThe Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer: An Open-Label, Randomized Controlled, Multicenter Clinical Study (Truce-LB02)

Aug 11, 2026TrialA Prospective, Multicenter, Randomized Controlled Study of Disitamab Vedotin Plus Toripalimab With or Without Pelvic Lymph Node Dissection for Bladder-Sparing Treatment in Patients With cT2-3N0M0 Bladder Urothelial Carcinoma

Jul 18, 2026TrialELEVATE Study: A Phase II Single-Arm Open-Label Single-Center Exploratory Trial of Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Advanced Refractory Solid Tumors With EGFR-Positive

3 more events

Jul 15, 2026TrialA Single-arm, Open Clinical Trial of Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)

Jul 14, 2026TrialDevelopment and External Validation of an Imaging-Clinical Multimodal Fusion Model for Predicting Postoperative Prognosis After Partial Nephrectomy in Patients With Endophytic Renal Cell Carcinoma

Jun 26, 2026TrialClinical Efficacy and Safety of Radical Nephroureterectomy With Versus Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma: A Multicenter, Prospective, Randomized Controlled Clinical Trial

Details